DIAX vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DIAX presents a complex profile characterized by a stable Piotroski F-Score of 5/9 and a significant valuation gap, trading well below its Graham Number of $23.45. While the Price-to-Book ratio of 0.83 suggests the fund is undervalued relative to its assets, this is offset by a completely bearish technical trend (0/100) and negative revenue growth. The fund's primary purpose as an overwrite fund is undermined by an extremely low dividend yield of 0.09%. Overall, the asset is a value play trapped in a strong bearish momentum cycle.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
DIAX vs JPM: Head-to-Head Comparison
This page compares Nuveen Dow 30 Dynamic Overwrite Fund (DIAX) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.